EVIDENCE LIBRARY
Valproate formulation and rescue sedation: what PRN medication counts actually measure
A retrospective study linked valproate formulation with combined rescue antipsychotic or benzodiazepine use, but the outcome was a prescribing proxy rather than a direct agitation score.
A retrospective study linked valproate formulation with combined rescue antipsychotic or benzodiazepine use, but the outcome was a prescribing proxy rather than a direct agitation score.
The comparison in the paper
Investigators examined records from 150 psychiatric inpatients receiving immediate-release, delayed-release, or extended-release valproate. They compared the average daily number of as-needed doses given for agitation. Valproate formulation remained associated with the combined antipsychotic-or-benzodiazepine outcome after adjustment for recorded characteristics. An association was also reported for antipsychotic doses alone.
Those findings should not be rewritten as proof that a particular formulation independently reduced benzodiazepine requirements. The combined endpoint can change because of its antipsychotic component, its benzodiazepine component, or both.
Why rescue doses need context
Rescue medication use reflects clinical symptoms, but also staff decisions, available orders, unit practices, and whether a patient accepts treatment. The study did not measure valproate serum concentrations, albumin, or missed valproate doses. Groups were relatively small and differed in some baseline characteristics.
For forensic or clinical review, obtain administration records rather than relying only on the medication list. Separate the drug class, reason for each rescue dose, and observation supporting it. The study identifies a relationship worth further testing; it does not establish a causal formulation effect or justify assuming that fewer PRN entries necessarily mean less agitation.
Source paper
Original analysis of the supplied journal article, identified as PMC12926606.